Funding · Healthcare & Life Sciences

eNLife Research raises ₹6 crore seed funding

What they do

ENLife Research uses AI to detect Alzheimer's and neurodegenerative disorders through blood biomarkers

It raised ₹6 crore in seed funding led by Piper Serica VC Fund

The platform is tailored to Indian genetic profiles, addressing a gap in existing diagnostic models

eNLife Research has raised ₹6 crore in seed funding.
The round was led by Piper Serica VC Fund.
The company is developing an AI-powered blood biomarker platform for early detection of Alzheimer's and neurodegenerative disorders.
The platform can detect signs up to 15 years before clinical symptoms appear.
It screens 5-7 biomarkers including amyloid beta and abnormal tau through a blood test.
Results are delivered within 2-5 hours through routine diagnostic centres.
The company plans to expand its R&D team in Bengaluru and advance its first diagnostic assay to clinical-grade.

Existing diagnostic models are developed on Western populations and are not accurate for Indian patients due to genetic and lifestyle differences.
India is expected to have the fastest-growing ageing population, making early diagnosis critical.
Conventional methods like PET scans, MRI scans, and cerebrospinal fluid analysis are expensive, invasive, and used late.

Its blood test screens 5-7 biomarkers including amyloid beta and abnormal tau.
Next-generation assays will track 25-100 biomarkers for multiple dementias and neurodegenerative disorders.
Results are available within 2-5 hours through routine diagnostic centres.
The AI engine is trained on Indian population data, tailored to Indian genetic and lifestyle risk profiles.
The company collaborates with IISc, NIMHANS, TIFR Hyderabad, and Centre for Brain Research (CBR) Bengaluru.
It was incubated at FSID, Indian Institute of Science (IISc).
Headquarters are in Bengaluru, and the company was founded in 2025.

Expand the R&D team in Bengaluru.
Validate the biomarker platform.
Advance the first diagnostic assay from prototype to clinical-grade.
Begin patent filing within 9-18 months covering biomarker binders, diagnostic assays, and detection platform.

Piper Serica VC Fund (lead) — Piper Serica's Bharat Tech Fund is ₹800 crore and backs AI, biosciences, semiconductors, defence tech, spacetech, and cybersecurity. Its director is Rajni Agarwal.

Product: Blood-based biomarker platform using AI to detect early signs of Alzheimer's and neurodegenerative diseases
Customers: Diagnostic centres, healthcare providers, and patients seeking early disease detection
How it makes money: Direct-to-consumer or B2B partnerships with diagnostic centres for biomarker testing services
What sets it apart: Designed specifically around Indian genetic and lifestyle risk profiles with results within two to five hours
Operations: R&D operations in Bengaluru focusing on biomarker detection and machine learning